Geron Corporation GERN
1.02 USD +0.05 (+4.70%)
At closeNov 11, 2026, 5:25 PM EST
1.02 0.00 0.00%
After hours · Nov 11, 5:25 PM ET
0.9649 Day range 1.02
0.84 52-week range 2.01
- YTD
- -22.73%
- 1 year
- -18.40%
News
marketbeat.com Geron Targets Germany Launch and Deals as RYTELO Sales Grow Geron NASDAQ: GERN is focusing on expanding U.S. use of its blood cancer drug RYTELO, preparing for a commercial sale in Germany and evaluating potential deals after discontinuing a late-stage trial…
defenseworld.net Geron (NASDAQ:GERN) & MDxHealth (NASDAQ:MDXH) Critical Review Geron (NASDAQ: GERN - Get Free Report) and MDxHealth (NASDAQ: MDXH - Get Free Report) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two…
fool.com Geron: 3 Key Takeaways for Long-Term Investors RYTELO quarterly net product revenue rose 27% year over year. Geron discontinued its Phase III trial in relapsed myelofibrosis.
marketbeat.com Geron Q3 Earnings Call Highlights Geron NASDAQ: GERN reported third-quarter net product revenue of $60.1 million for RYTELO, a 27% increase from $47.2 million a year earlier, as the company cited continued growth in prescribing,…
seekingalpha.com Geron Corporation (GERN) Q3 2026 Earnings Call Transcript Geron Corporation (GERN) Q3 2026 Earnings Call Transcript
zacks.com Geron (GERN) Reports Break-Even Earnings for Q3 Geron (GERN) reported break-even quarterly earnings per share versus the Zacks Consensus Estimate of a loss of $0.01. This compares to a loss of $0.03 per share a year ago.
benzinga.com Geron To Present Six Abstracts At 68th American Society Of Hematology Annual Meeting Geron Corporation (Nasdaq: GERN), a hematology-focused commercial stage biopharmaceutical company pursuing more meaningful moments for people living with blood cancer, today announced that six…
globenewswire.com Geron Corporation to Present Data Highlighting Clinical and Biological Activity of RYTELO® (imetelstat) at ASH 2026 FOSTER CITY, Calif., Nov. 04, 2026 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN), a hematology-focused commercial stage biopharmaceutical company pursuing more meaningful moments for people…
benzinga.com Geron Q3 2026 Earnings Call Transcript Geron (NASDAQ:GERN) reported third-quarter financial results on Wednesday. The transcript from the company’s third-quarter earnings call has been provided below.Benzinga APIs provide real-time access…
globenewswire.com Geron Corporation Reports Third Quarter 2026 Financial Results and Recent Business Highlights Achieved $60.1 million in RYTELO ® (imetelstat) net product revenue in Q3 2026, an increase of 5% compared to Q2 2026
benzinga.com Wedbush Maintains Outperform on Geron, Lowers Price Target to $5 Wedbush analyst Robert Driscoll maintains Geron (NASDAQ:GERN) with a Outperform and lowers the price target from $6 to $5.
benzinga.com Penny Stock Geron Ends Advanced Cancer Study, Shifts Focus to Commercial Growth Geron stock plunges as the company halts its Phase 3 IMpactMF trial, refocusing its resources on commercial hematology and global expansion.
benzinga.com Crude Oil Surges Over 3%; Brinker Posts Upbeat Earnings U.S. stocks were mixed; Dow and S&P 500 rose while Nasdaq slipped. Brinker beat estimates and raised guidance; oil jumped 3.4%.
benzinga.com Geron Q2 2026 Earnings Call: Complete Transcript Geron (NASDAQ:GERN) held its second-quarter earnings conference call on Wednesday. Below is the complete transcript from the call. This transcript is brought to you by Benzinga APIs. For real-time…
benzinga.com Geron To Present Real-World Moffitt Cancer Center Study Showing RYTELO (imetelstat) Safety And Efficacy In Lower-Risk MDS At EHA 2026 Investigator-sponsored study, conducted at the Moffitt Cancer Center, demonstrates safety and efficacy consistent with the Phase 3 IMerge trial in a broader patient population Additional…
benzinga.com Earnings Scheduled For May 6, 2026 
benzinga.com Geron Reports Q1 2026 Results: Full Earnings Call Transcript 
benzinga.com Geron Q1 EPS $(0.01) Beats $(0.02) Estimate, Sales $51.771M Beat $50.582M Estimate Geron (NASDAQ:GERN) reported quarterly losses of $(0.01) per share which beat the analyst consensus estimate of $(0.02) by 50 percent. This is a 66.67 percent increase over losses of $(0.03) per…
benzinga.com Fastenal, Replimune Group, Children's Place And Other Big Stocks Moving Lower In Monday's Pre-Market Session U.S. stock futures lower, with Dow futures down 150 points. Fastenal shares dip 4% after meeting earnings estimate. Other stocks also down.- benzinga.com 12 Health Care Stocks Moving In Wednesday's Intraday Session
benzinga.com Earnings Summary: Geron Q4 - benzinga.com Geron Q4 EPS $(0.05) Misses $(0.03) Estimate, Sales $48.015M Miss $50.420M Estimate Geron (NASDAQ:GERN) reported quarterly losses of $(0.05) per share which missed the analyst consensus estimate of $(0.03) by 47.06 percent. This is a 25 percent decrease over losses of $(0.04) per…
- benzinga.com Earnings Scheduled For February 25, 2026
benzinga.com Top 2 Tech Stocks That May Fall Off A Cliff This Quarter 
benzinga.com Top 2 Industrials Stocks That Are Ticking Portfolio Bombs 
benzinga.com Top 3 Health Care Stocks That May Collapse This Quarter 
benzinga.com Investor Says He 'Doubled' His Savings After Using ChatGPT in Stock Research – Shares Top 5 Stock Picks - benzinga.com Geron Implements Strategic Restructuring, Cutting Workforce By One-Third And Incurring ~$18M In Charges On December 16, 2025, Geron Corporation (the "Company") began implementation of a strategic restructuring plan intended to position the Company for long-term value creation for patients and…
benzinga.com Why Planet Labs Shares Are Trading Higher By Around 16%; Here Are 20 Stocks Moving Premarket - benzinga.com Geron Showcases New ASH 2025 Data Highlighting RYTELO's Durable Efficacy And Survival Trends Across LR-MDS And Myelofibrosis Oral presentation from pooled analyses of the IMerge population suggests that treatment-emergent cytopenias may reflect on-target effects associated with meaningful clinical outcomes, including…
benzinga.com Geron Expects 2025 Operating Expenses Will Be Between $250M And $260M vs. Approximately $270M-$285M Prior 2025 Financial GuidanceFor fiscal year 2025, the Company expects total operating expenses will be between $250 million and $260 million, compared to previously announced guidance of approximately…
benzinga.com Earnings Scheduled For November 5, 2025 
benzinga.com Geron Earnings Preview - benzinga.com Geron To Present New RYTELO Data On LR-MDS And Myelofibrosis At ASH 2025 New analysis from the Phase 3 IMerge clinical trial, accepted as an oral presentation, explores relationship between treatment-emergent cytopenias and clinical response in LR-MDSAdditional poster…
- benzinga.com Geron's COO Andrew Grethlein To Depart On October 15, 2025 FOSTER CITY, Calif., Oct. 13, 2025 (GLOBE NEWSWIRE) -- Geron Corporation (NASDAQ:GERN), a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer,…
- benzinga.com 12 Health Care Stocks Moving In Wednesday's Pre-Market Session
- benzinga.com Geron Q2 EPS $(0.02) Beats $(0.03) Estimate, Sales $49.036M Beat $47.281M Estimate Geron (NASDAQ:GERN) reported quarterly losses of $(0.02) per share which beat the analyst consensus estimate of $(0.03) by 33.33 percent. This is a 80 percent increase over losses of $(0.10) per…
- benzinga.com Earnings Scheduled For August 6, 2025
benzinga.com Goldman Sachs Reinstates Sell on Geron, Announces $1 Price Target Goldman Sachs analyst Corinne Jenkins reinstates Geron (NASDAQ:GERN) with a Sell and announces $1 price target.- benzinga.com Goldman Sachs Initiates Coverage On Geron with Sell Rating, Announces Price Target of $1 Goldman Sachs analyst Corinne Jenkins initiates coverage on Geron (NASDAQ:GERN) with a Sell rating and announces Price Target of $1.
benzinga.com Geron Highlights New IMerge Post-Hoc Analyses Demonstrating RYTELO's Clinical Benefit In Lower-Risk MDS Patients Across Key Subgroups, Alongside Quality-of-Life And Transfusion Independence Data At ASCO And EHA 2025 New post-hoc analyses from the IMerge trial show clinical benefit with RYTELO across patients with lower-risk myelodysplastic syndromes (LR-MDS), regardless of ring sideroblast status, baseline serum…
benzinga.com 12 Health Care Stocks Moving In Wednesday's Pre-Market Session - benzinga.com Geron Q1 EPS $(0.03) Beats $(0.04) Estimate, Sales $39.60M Miss $48.22M Estimate Geron (NASDAQ:GERN) reported quarterly losses of $(0.03) per share which beat the analyst consensus estimate of $(0.04) by 25 percent. This is a 66.67 percent increase over losses of $(0.09) per…
- benzinga.com Earnings Scheduled For May 7, 2025
- benzinga.com 10 Health Care Stocks Whale Activity In Today's Session
- benzinga.com Scotiabank Maintains Sector Outperform on Geron, Lowers Price Target to $4 Scotiabank analyst Greg Harrison maintains Geron (NASDAQ:GERN) with a Sector Outperform and lowers the price target from $6 to $4.
- benzinga.com Stifel Maintains Buy on Geron, Lowers Price Target to $4 Stifel analyst Stephen Willey maintains Geron (NASDAQ:GERN) with a Buy and lowers the price target from $8 to $4.
- benzinga.com Barclays Maintains Overweight on Geron, Lowers Price Target to $4 Barclays analyst Peter Lawson maintains Geron (NASDAQ:GERN) with a Overweight and lowers the price target from $9 to $4.
benzinga.com Needham Maintains Buy on Geron, Lowers Price Target to $5 Needham analyst Gil Blum maintains Geron (NASDAQ:GERN) with a Buy and lowers the price target from $7 to $5.
benzinga.com Dow Dips Over 100 Points; TJX Earnings Top Views